Furthermore, unlike other immunotherapies, such as immune checkpoint inhibitors that aim to reverse the exhaustion state of T cells, TLR9 agonist combined with RT causes activated CD8+ T cells that are not yet exhausted to infiltrate the tumor and enhance the radiation response. This evidence concerns the gene TLR9 and neoplasm.